Merck & Co Announce Increased Profit for Q1

merck_logo_detailMerck & Co’s have released their Q1 results for 2014, showing an increase in profit, despite being hindered by unfavourable exchange rates and patents expiring.

The healthcare company announced net income of $1.70 billion, an increase from the $1.59 billion net income of Merck & Co’s first quarter of 2013.  However, turnover for the business dropped by 4% to $10.26 billion.

Sales of Merck & Co’s asthma blockbuster, Singulair (montelukast), fell 20% to $271 million, while Nasonex (mometasone), an anti-allergy medicine, also decreased 19% to $312 million.

HIV drug, Isentress (raltegravir), reached $390 million, an increase of 8%, while turnover from Merck & Co’s cervical cancer vaccine, Gardasil, dropped 2% to $383 million.  Janumet (sitagliptin plus metformin) brought in revenue of $476 million, a rise of 16%.  Diabetes drug, Januvia (sitagliptin), also fell slightly generating $858 million, a drop of 3%.

Cholesterol drugs, Vytorin (ezetimibe plus simvastatin) and Zetia (ezetimibe), contributed sales of $361 million and $611 million, dropping 8% and 3% respectively.  Johnson & Johnson’s anti-inflammatory drug, Remicade (infliximab), which Merck sells outside the USA, received sales of $604 million, growing 10%.

Merck & Co’s chief executive, Kenneth Frazier, noted that “investing in the best opportunities for growth while being disciplined in managing our costs enabled us to deliver bottom-line performance.”

Frazier added “this is an exciting time as we prepare to commercialise the next wave of innovation coming out of Merck’s research labs over the next few years.”


News, Industry News